HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: a systematic review and meta-analysis

Breast cancer (BC) with overexpression and/or amplification of the Human Epidermal Growth Factor Receptor 2 (HER2-positive) represents 11-30% of all breast tumors[1]. HER2 positivity is defined today by immunohistochemistry (IHC) as complete and strong membrane staining (i.e. score of 3+) in ≥10% of cancer cells, and/or by in situ immunofluorescence (ISH) techniques as amplified using a HER2/CEP17 ratio cutoff of ≥ 2.0 and an average HER2 gene copy number ≥ 4.0 signals per cell[2]. This consensus definition is based on the methods and cutoffs used over the years in pivotal trials that led to the approval of trastuzumab[3], pertuzumab[4], neratinib[5], lapatinib[6] and T-DM1[7] in HER2+ breast cancer.
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Systematic or Meta-analysis Studies Source Type: research